439 related articles for article (PubMed ID: 28624478)
21. Albumin-Based Nanodevices as Drug Carriers.
Loureiro A; Azoia NG; Gomes AC; Cavaco-Paulo A
Curr Pharm Des; 2016; 22(10):1371-90. PubMed ID: 26806342
[TBL] [Abstract][Full Text] [Related]
22. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
23. Classification of stimuli-responsive polymers as anticancer drug delivery systems.
Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z
Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737
[TBL] [Abstract][Full Text] [Related]
24. Application of hyaluronic acid as carriers in drug delivery.
Huang G; Huang H
Drug Deliv; 2018 Nov; 25(1):766-772. PubMed ID: 29536778
[TBL] [Abstract][Full Text] [Related]
25. Cancer nanomedicine: from targeted delivery to combination therapy.
Xu X; Ho W; Zhang X; Bertrand N; Farokhzad O
Trends Mol Med; 2015 Apr; 21(4):223-32. PubMed ID: 25656384
[TBL] [Abstract][Full Text] [Related]
26. Nanocarriers for anticancer drugs--new trends in nanomedicine.
Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
[TBL] [Abstract][Full Text] [Related]
27. Thiol redox-sensitive cationic polymers for dual delivery of drug and gene.
Syamala PS; Ramesan RM
Ther Deliv; 2018 Oct; 9(10):751-773. PubMed ID: 30277132
[TBL] [Abstract][Full Text] [Related]
28. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications.
Chakraborty S; Dhakshinamurthy GS; Misra SK
J Biomed Mater Res A; 2017 Oct; 105(10):2906-2928. PubMed ID: 28643475
[TBL] [Abstract][Full Text] [Related]
29. Stimuli-sensitive nanopreparations for combination cancer therapy.
Jhaveri A; Deshpande P; Torchilin V
J Control Release; 2014 Sep; 190():352-70. PubMed ID: 24818767
[TBL] [Abstract][Full Text] [Related]
30. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
31. Targeting carbon nanotubes against cancer.
Fabbro C; Ali-Boucetta H; Da Ros T; Kostarelos K; Bianco A; Prato M
Chem Commun (Camb); 2012 Apr; 48(33):3911-26. PubMed ID: 22428156
[TBL] [Abstract][Full Text] [Related]
32. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
[TBL] [Abstract][Full Text] [Related]
33. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in peptide nucleic acid for cancer bionanotechnology.
Wu JC; Meng QC; Ren HM; Wang HT; Wu J; Wang Q
Acta Pharmacol Sin; 2017 Jun; 38(6):798-805. PubMed ID: 28414202
[TBL] [Abstract][Full Text] [Related]
35. Calcium phosphate nanocarriers for drug delivery to tumors: imaging, therapy and theranostics.
Huang D; He B; Mi P
Biomater Sci; 2019 Oct; 7(10):3942-3960. PubMed ID: 31414096
[TBL] [Abstract][Full Text] [Related]
36. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
37. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs.
Markovsky E; Baabur-Cohen H; Satchi-Fainaro R
J Control Release; 2014 Aug; 187():145-57. PubMed ID: 24862318
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
[TBL] [Abstract][Full Text] [Related]
39. Nanomedicine: the promise and challenges in cancer chemotherapy.
Naguib YW; Cui Z
Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
[No Abstract] [Full Text] [Related]
40. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
